| Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP … S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, ... Blood 102 (1), 276-283, 2003 | 990 | 2003 |
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ... Journal of clinical oncology 27 (32), 5410, 2009 | 849 | 2009 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 559 | 2017 |
| Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (22), 5827-5834, 2011 | 538 | 2011 |
| Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations S Branford, Z Rudzki, I Parkinson, A Grigg, K Taylor, JF Seymour, ... Blood 104 (9), 2926-2932, 2004 | 292 | 2004 |
| Autologous haematopoietic stem cell transplants for autoimmune disease–feasibility and transplant-related mortality A Tyndall, A Fassas, J Passweg, C Ruiz de Elvira, M Attal, P Brooks, ... Bone marrow transplantation 24 (7), 729-734, 1999 | 271 | 1999 |
| Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. JA Snowden, J Passweg, JJ Moore, S Milliken, P Cannell, J Van Laar, ... The Journal of Rheumatology 31 (3), 482-488, 2004 | 212 | 2004 |
| A pilot randomized trial comparing CD34‐selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis J Moore, P Brooks, S Milliken, J Biggs, D Ma, M Handel, P Cannell, R Will, ... Arthritis & Rheumatism 46 (9), 2301-2309, 2002 | 208 | 2002 |
| Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase S Branford, Z Rudzki, A Harper, A Grigg, K Taylor, S Durrant, C Arthur, ... Leukemia 17 (12), 2401-2409, 2003 | 203 | 2003 |
| Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy TP Hughes, S Branford, DL White, J Reynolds, R Koelmeyer, JF Seymour, ... Blood, The Journal of the American Society of Hematology 112 (10), 3965-3973, 2008 | 201 | 2008 |
| Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study JA Royle, PD Baade, D Joske, J Girschik, L Fritschi British journal of cancer 105 (7), 1076-1081, 2011 | 150 | 2011 |
| Haematological cancer patients: achieving a sense of empowerment by use of strategies to control illness C Bulsara, A Ward, D Joske Journal of clinical nursing 13 (2), 251-258, 2004 | 120 | 2004 |
| Autologous bone-marrow transplantation for rheumatoid arthritis DJL Joske The Lancet 350 (9074), 337-338, 1997 | 113 | 1997 |
| When the safety net of treatment has been removed: patients’ unmet needs at the completion of treatment for haematological malignancies EA Lobb, D Joske, P Butow, LJ Kristjanson, P Cannell, G Cull, ... Patient education and counseling 77 (1), 103-108, 2009 | 111 | 2009 |
| Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion BJ Cohen, S Beard, WA Knowles, JS Ellis, D Joske, JM Goldman, ... Transfusion 37 (9), 947-952, 1997 | 111 | 1997 |
| Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006 MT Van Leeuwen, JJ Turner, DJ Joske, MO Falster, P Srasuebkul, ... International journal of cancer 135 (9), 2146-2156, 2014 | 94 | 2014 |
| Australasian haematologist referral patterns to palliative care: lack of consensus on when and why K Auret, C Bulsara, D Joske Internal medicine journal 33 (12), 566-571, 2003 | 92 | 2003 |
| Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma LM Cunningham, C Chapman, R Dunstan, MC Bell, DJL Joske Leukemia & lymphoma 44 (2), 251-255, 2003 | 91 | 2003 |
| Significant association between thyroid hormones and erythrocyte indices in euthyroid subjects AP Bremner, P Feddema, DJ Joske, PJ Leedman, PC O’Leary, JK Olynyk, ... Clinical endocrinology 76 (2), 304-311, 2012 | 90 | 2012 |
| Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation A Spencer, N Horvath, J Gibson, HM Prince, R Herrmann, J Bashford, ... Bone marrow transplantation 35 (10), 971-977, 2005 | 85 | 2005 |
